Loading...
•
Sep 30, 2024
MacroGenics Q3 2024 Earnings Report
MacroGenics' financial position was strengthened by the MARGENZA transaction and Incyte milestone payment, and the IND application for ADAM9-directed ADC (MGC028) was submitted to the FDA.
Key Takeaways
MacroGenics reported total revenue of $110.7 million for Q3 2024, primarily driven by a $100.0 million milestone payment from Incyte. Net income was $56.3 million. The company's cash, cash equivalents, and marketable securities balance was $200.4 million as of September 30, 2024.
Financial position strengthened by MARGENZA transaction and Incyte milestone payment.
ADAM9-directed ADC (MGC028) IND application submitted to FDA.
Total revenue for Q3 2024 was $110.7 million, primarily due to a $100 million milestone from Incyte.
Net income for Q3 2024 was $56.3 million.
MacroGenics
MacroGenics
MacroGenics Revenue by Segment
Revenue by Segment
Product sales, net Revenue
CapyFin.comContract manufacturing Revenue
CapyFin.comGovernment agreements Revenue
CapyFin.com Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $200.4 million as of September 30, 2024, plus the $40.0 million upfront payment anticipated from TerSera related to the MARGENZA transaction, less an $8.0 million amendment fee to be paid to the Company’s current commercialization partner, in addition to projected and anticipated future payments from partners should support its cash runway into 2026.
Positive Outlook
- Cash runway extended into 2026.
- Upfront payment of $40.0 million anticipated from TerSera.
- Projected and anticipated future payments from partners.
- Focus on completing Phase 2 TAMARACK and LORIKEET clinical trials.
- Advancement of other ongoing clinical and preclinical studies.
Challenges Ahead
- Amendment fee of $8.0 million to be paid to the Company's current commercialization partner.
- Expenditures related to the completion of the Phase 2 TAMARACK and LORIKEET clinical trials.
- Expenditures related to MacroGenics’ other ongoing clinical and preclinical studies.
- Uncertainties inherent in the initiation and enrollment of future clinical trials.
- Availability and timing of data from ongoing clinical trials.
Revenue & Expenses
Visualization of income flow from segment revenue to net income